NCT07754994Not yet recruiting
Medication Self-Management Technology for Older Adults
Remote Hypertension Medication Self-Management Technology for Older Adults
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The goal of this feasibility study is to evaluate the preliminary impact of a mobile health application (app) called bpMedManage-R, designed to support hypertension medication self-management in persons with mild cognitive impairment (PwMCI) who live alone. The main questions this study aims to answer are whether the bpMedManage-R app shows preliminary impact on medication-related self-regulation (the ability to consistently take medications as prescribed) and self-efficacy (confidence in independently managing medication use). Participants will be randomized after a baseline assessment to the bpMedManage-R Immediate Group or the bpMedManage-R Delayed Group. Participants assigned to the Immediate Group will complete a 4-week baseline adherence period, at the end of which they will enter the intervention phase. A remote training session will be conducted to initiate the intervention phase, during which participants will download the app, learn to use it, and set up their medication schedule and reminders within the app with support from the study team. They will then use the app for 8 weeks to self-manage their medications, take part in brief weekly check-ins to review progress, and complete Outcome Assessment 1 at the end of the 8-week intervention phase. Participants assigned to the Delayed Group will complete a 12-week baseline adherence period, at the end of which they will complete Outcome Assessment 1. Subsequently, they will enter the intervention phase and will follow a process similar to that of the Immediate Group. At the end of the 8-week intervention phase, they will complete Outcome Assessment 2. Researchers will compare participants who receive the bpMedManage-R app intervention immediately to those assigned to the delayed control group.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- Oct 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Diseases
- High blood pressure
- NCT number
- NCT07754994
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Oct 2026 to the primary completion date, Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of dementia
Other
- Major communication difficulties
Who the study is looking for
- Age 60+
- Fluent in English
- Adequate visual and auditory acuity
- Community dwelling
- Lives alone
- Self-reported memory problems
- Manage at least one hypertension medication
- Passing score on Telephone Interview for Cognitive Status - Modified (TICS- M) between 27-37
- Passing score on Montreal Cognitive Assessment (MoCA) between 20 and 26
- Geriatric Depression Scale (GDS) score of 6 or lower
- Stated willingness to comply with all study procedures and availability for the duration of the study
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.